Neurological disorder diagnostic tools are used for the diagnosis of various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and others. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostic techniques. Imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels, and other parts of body. Whereas, in-vitro diagnostic techniques include biopsy, biomarker, blood test, urine test, and genetic testing.
Market Dynamics
Technological innovations and developments in neurological disorder diagnosing devices are expected to drive the market growth. For instance, in 2017, Neusoft Medical Systems developed an innovative CT scanner NeuViz Prime CT Scanner and received the U.S. Food and Drug Administration approval for the system. Moreover in 2016, Koninklijke Philips N.V. launched IQon Spectral CT in Canada. IQon Spectral CT is a spectral detector CT, designed specifically for spectral imaging.
Key features of the study:
- This report provides in-depth analysis of the global neurological disorder diagnostics market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neurological disorder diagnostics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
- The global neurological disorder diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurological disorder diagnostics market
Detailed Segmentation:
- Global Neurological Disorder Diagnostics Market, By Technology:
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- Global Neurological Disorder Diagnostics Market, By Disease Indication:
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- Global Neurological Disorder Diagnostics Market, By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Ambulatory Care Centers
- Global Neurological Disorder Diagnostics Market, By Region:
- North America
- By Technology:
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- By Disease Indication:
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Ambulatory Care Centers
- By Country:
- Latin America
- By Technology:
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- By Disease Indication:
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Ambulatory Care Centers
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Technology:
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- By Disease Indication:
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Ambulatory Care Centers
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- By Technology:
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- By Disease Indication:
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Ambulatory Care Centers
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Technology:
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- By Disease Indication:
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Ambulatory Care Centers
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Technology:
- Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging
- Positron Emission Tomography (PET)
- Single-photon Emission Computed Tomography (SPECT)
- Near Infrared Spectroscopic Imaging (NIRS)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- By Disease Indication:
- Genetic Neurological Disorders
- Alzheimer’s Disease (AD)
- Parkinson’s Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease (HD)
- Others
- Immunological Neurological Disorders
- Multiple Sclerosis
- Others
- Paraneoplastic Syndrome
- Paraproteinemic Neuropathies
- Others
- By End User:
- Hospitals & Clinics
- Diagnostic Centers
- Ambulatory Care Centers
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Siemens Healthineers *
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Koninklijke Philips N.V.
- General Electric Company
- Esaote SpA
- NeuroLogica Corporation
- Masimo Corporation
- York Instruments Ltd
- Neusoft Medical Systems
- Canon Medical Systems Corporation
“*” marked represents similar segmentation in other categories in the respective section.
